Skip to content
OpenCapital
Get started

Baxter International BAX Pharmaceuticals — Segment operating income

Other segment segments

Reportable Segment
$298M-25.5%
Medical Products & Therapies
$186M-23.8%
Healthcare Systems & Technologies
$66M-29.0%

Similar metrics at other companies

Becton, Dickinson and Company logo
BDXBioPharma Systems — Segment Operating Income (Loss) as a Percent of Revenues
38.1%-0.8pp
AptarGroup logo
ATRPharma — Income Loss From Continuing Operations Before Interest Expense Interest Income Income Taxes Extraordinary Items Noncontrolling Interests Net
6,050,200,000%+833,300,000pp
Labcorp Holdings logo
LHBiopharma Laboratory Services — Operating Income
$120.7M+12.9%
Becton, Dickinson and Company logo
BDXBioPharma Systems — Segment Other Operating Expense (Income), net as a Percent of Revenues
0%—
AptarGroup logo
ATRPharma — Adjustedincomelossfromcontinuingoperationsbeforeinterestexpenseinterestincomeincometaxesdepreciationamortizationextraordinaryitemsnoncontrollinginterestsnet
$111.01M+4.7%
BrightSpring Health Services, Inc. logo
BTSGPharmacy Solutions — Earnings Before Interest Income Taxes Depreciation And Amortization From Reportable
$169.07M+46.1%

Other financials

Income statement

See full
Revenue$2.7B+2.9%
Gross profit$891.0M+3.5%
Operating income$66.0M+13.8%
Net income-$15.0M-112%
EPS (diluted)-$0.03-112%

Balance sheet

See full
Cash & equivalents$2.0B-12.1%
Total debt$224.0M-8.9%
Total equity$6.0B-14.7%
Total assets$19.8B-6.8%

Cash flow

See full
Operating cash flow$213.0M+210%
CapEx$128.3M+15.0%
Free cash flow$83.0M-42.1%

Valuation

See full
Market cap$10.27B-50.6%
Enterprise value$8.48B-55.6%
P/S0.9×-1.0×

Profitability

See full
Gross margin30.1%-5.9pp
Operating margin-2.7%—
Net margin-9.7%+62.5pp
FCF margin3%-2.4pp

Returns & leverage

See full
Return on equity-16.7%-76.7pp
Debt / equity0×0.0×
Current ratio1.9×-0.2×

Where this comes from

Reported directly by Baxter International in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The official record: Baxter International’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Baxter International's pharmaceuticals — segment operating income.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Baxter International's pharmaceuticals — segment operating income?
Baxter International (BAX) reported pharmaceuticals — segment operating income of $46M in Q1 2026.
How has Baxter International's pharmaceuticals — segment operating income changed year-over-year?
Baxter International's pharmaceuticals — segment operating income decreased by 27.0% year-over-year, from $63M to $46M.
What is the long-term trend for Baxter International's pharmaceuticals — segment operating income?
Over 3 years (2021 to 2025), Baxter International's pharmaceuticals — segment operating income has grown at a -24.8% compound annual growth rate (CAGR), from $523M to $222M.
What does pharmaceuticals — segment operating income mean?
The profit generated by the Pharmaceuticals segment from its core business activities.
How do you interpret pharmaceuticals — segment operating income?
Higher operating income indicates strong profitability and efficient management of the segment's resources.
How does pharmaceuticals — segment operating income compare across companies?
A primary metric for comparing segment-level performance against industry competitors.